Nasdaq Grants PAVmed 180-Day Extension to Meet Minimum Bid Price Rule

PAVmed has been granted a 180-day extension by Nasdaq to regain compliance with the $1.00 minimum bid price rule. The company's shares will continue trading on the Nasdaq Capital Market without immediate delisting risk. PAVmed must achieve a closing bid price of at least $1.00 per share for ten consecutive business days by January 19, 2026.

PAVmed Inc. (Nasdaq: PAVM), a commercial-stage medical technology company, has been granted a 180-day extension by Nasdaq to regain compliance with the $1.00 minimum bid price rule. The company now has until January 19, 2026, to maintain a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days [1].

The notification does not immediately affect PAVmed's listing status, and its shares will continue trading on the Nasdaq Capital Market under the symbol "PAVM" [2]. The company has stated its intention to take appropriate actions to cure the deficiency and regain compliance before the extended deadline [3].

PAVmed operates in the medical device, diagnostics, and digital health sectors. Its subsidiaries, Lucid Diagnostics and Veris Health Inc., are developing innovative products for early detection of esophageal precancer and personalized cancer care, respectively. Despite the current compliance issue, the company's shares will continue to be traded on the Nasdaq Capital Market without immediate delisting risk [2].

For more information about PAVmed, please visit pavmed.com. For information about Lucid Diagnostics, please visit luciddx.com. For more information about Veris Health, please visit verishealth.com.

References:
[1] https://www.stocktitan.net/news/PAVM/pa-vmed-granted-180-day-extension-by-nasdaq-to-regain-compliance-tatmgj1ct8a9.html
[2] https://www.gurufocus.com/news/3016409/pavmed-granted-180day-extension-by-nasdaq-to-regain-compliance-with-minimum-bid-price-rule-pavm-stock-news
[3] https://www.prnewswire.com/news-releases/pavmed-granted-180-day-extension-by-nasdaq-to-regain-compliance-with-minimum-bid-price-rule-302517016.html